Plasma Clusterin Concentrations May Predict Resistance to Intravenous Immunoglobulin in Patients with Kawasaki Disease

Table 3

Plasma biomarkers in patients with Kawasaki disease who had a response to IVIG or were IVIG resistant.

Biomarker	Response (𝑛=58)	Resistance (𝑛=5)	P value
CLUSTER 1	25.02±12.33	16.44±6.59	0.132
CLUSTER 2	23.09±12.59	27.70±10.14	0.429
CLUSTER 12	−1.93±13.66	11.26±11.17	0.040*
CLUSTER 012	1.33±0.90	0.64±0.35	0.097
FIB 1	1141.68±795.77	803.94±185.89	0.351
FIB 2	1513.52±1122.97	1258.25±946.08	0.624
FIB 12	371.85±726.86	454.31±895.55	0.812
FIB 012	0.83±0.34	0.82±0.31	0.934

CLUSTER 1 (mg/L): plasma clusterin concentration before IVIG treatment; CLUSTER 2 (mg/L): plasma clusterin concentration after IVIG treatment; CLUSTER 12 (mg/L): CLUSTER 2 − CLUSTER 1; CLUSTER 012: CLUSTER 2/CLUSTER 1; FIB 1 (mg/dL): plasma fibrinogen concentration before IVIG treatment; FIB 2 (mg/dL): plasma fibrinogen concentration after IVIG treatment; FIB 12 (mg/dL): FIB 2 – FIB 1; FIB 012: FIB 2/FIB 1. *P < 0.05 was considered statistically significant difference.